Literature DB >> 24877630

Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes.

Abdullah N Ben-awadh1, Jesus Delgado-Calle, Xiaolin Tu, Kali Kuhlenschmidt, Matthew R Allen, Lilian I Plotkin, Teresita Bellido.   

Abstract

PTH upregulates the expression of the receptor activator of nuclear factor κB ligand (Rankl) in cells of the osteoblastic lineage, but the precise differentiation stage of the PTH target cell responsible for RANKL-mediated stimulation of bone resorption remains undefined. We report that constitutive activation of PTH receptor signaling only in osteocytes in transgenic mice (DMP1-caPTHR1) was sufficient to increase Rankl expression and bone resorption. Resorption in DMP1-caPTHR1 mice crossed with mice lacking the distal control region regulated by PTH in the Rankl gene (DCR(-/-)) was similar to DMP1-caPTHR1 mice at 1 month of age, but progressively declined to reach values undistinguishable from wild-type (WT) mice at 5 months of age. Moreover, DMP1-caPTHR1 mice exhibited low tissue material density and increased serum alkaline phosphatase activity at 5 month of age, and these indices of high remodeling were partially and totally corrected in compound DMP1-caPTHR1;DCR(-/-) male mice, and less affected in female mice. Rankl expression in bones from DMP1-caPTHR1 mice was elevated at both 1 and 5 months of age, whereas it was high, similar to DMP1-caPTHR1 mice at 1 month, but low, similar to WT levels at 5 months in compound mice. Moreover, PTH increased Rankl and decreased Sost and Opg expression in ex vivo bone organ cultures established from WT mice, but only regulated Sost and Opg expression in cultures from DCR(-/-) mice. PTH also increased RANKL expression in osteocyte-containing primary cultures of calvarial cells, in isolated murine osteocytes, and in WT but not in DCR(-/-) osteocyte-enriched bones. Thus, PTH upregulates Rankl expression in osteocytes in vitro, ex vivo and in vivo, and resorption induced by PTH receptor signaling in the adult skeleton requires direct regulation of the Rankl gene in osteocytes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24877630      PMCID: PMC4098003          DOI: 10.1210/en.2014-1046

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  33 in total

1.  Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice.

Authors:  Amber Rath Stern; Matthew M Stern; Mark E Van Dyke; Katharina Jähn; Matthew Prideaux; Lynda F Bonewald
Journal:  Biotechniques       Date:  2012-06       Impact factor: 1.993

2.  Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer.

Authors:  Qiang Fu; Stavros C Manolagas; Charles A O'Brien
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

4.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

Review 5.  Osteocyte control of osteoclastogenesis.

Authors:  Charles A O'Brien; Tomoki Nakashima; Hiroshi Takayanagi
Journal:  Bone       Date:  2012-08-23       Impact factor: 4.398

6.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

Authors:  L I Plotkin; R S Weinstein; A M Parfitt; P K Roberson; S C Manolagas; T Bellido
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 7.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

8.  Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines.

Authors:  Y Sakagami; G Girasole; X P Yu; H S Boswell; S C Manolagas
Journal:  J Bone Miner Res       Date:  1993-07       Impact factor: 6.741

Review 9.  Effects of PTH on osteocyte function.

Authors:  Teresita Bellido; Vaibhav Saini; Paola Divieti Pajevic
Journal:  Bone       Date:  2012-09-24       Impact factor: 4.398

10.  Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.

Authors:  A Erlebacher; R Derynck
Journal:  J Cell Biol       Date:  1996-01       Impact factor: 10.539

View more
  38 in total

1.  Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6.

Authors:  Ning Zhao; Francisco H Nociti; Peipei Duan; Matthew Prideaux; Hong Zhao; Brian L Foster; Martha J Somerman; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2015-09-23       Impact factor: 6.741

2.  Aberrantly elevated Wnt signaling is responsible for cementum overgrowth and dental ankylosis.

Authors:  Yan Wu; Xue Yuan; Kristy C Perez; Sydnee Hyman; Liao Wang; Gretel Pellegrini; Benjamin Salmon; Teresita Bellido; Jill A Helms
Journal:  Bone       Date:  2018-10-25       Impact factor: 4.398

3.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

Review 4.  CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.

Authors:  Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 5.  Parathyroid Diseases and T Cells.

Authors:  M Neale Weitzmann; Roberto Pacifici
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 6.  Role and mechanism of action of sclerostin in bone.

Authors:  Jesus Delgado-Calle; Amy Y Sato; Teresita Bellido
Journal:  Bone       Date:  2016-10-12       Impact factor: 4.398

Review 7.  Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis.

Authors:  Eben G Estell; Clifford J Rosen
Journal:  Nat Rev Endocrinol       Date:  2020-11-04       Impact factor: 43.330

8.  Osteocyte Death and Bone Overgrowth in Mice Lacking Fibroblast Growth Factor Receptors 1 and 2 in Mature Osteoblasts and Osteocytes.

Authors:  Jennifer McKenzie; Craig Smith; Kannan Karuppaiah; Joshua Langberg; Matthew J Silva; David M Ornitz
Journal:  J Bone Miner Res       Date:  2019-06-17       Impact factor: 6.741

9.  Do antiosteoporotic drugs improve bone regeneration in vivo?

Authors:  Maximilian Leiblein; Dirk Henrich; Florian Fervers; Kerstin Kontradowitz; Ingo Marzi; Caroline Seebach
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-26       Impact factor: 3.693

Review 10.  Heterotrimeric G proteins in the control of parathyroid hormone actions.

Authors:  Murat Bastepe; Serap Turan; Qing He
Journal:  J Mol Endocrinol       Date:  2017-05       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.